首页> 美国卫生研究院文献>other >New N-substituted 9-azabicyclo3.3.1nonan-3α-yl phenylcarbamate analogs as σ2 receptor ligands: synthesis in vitro characterization and evaluation as PET imaging and chemosensitization agents
【2h】

New N-substituted 9-azabicyclo3.3.1nonan-3α-yl phenylcarbamate analogs as σ2 receptor ligands: synthesis in vitro characterization and evaluation as PET imaging and chemosensitization agents

机译:新的N-取代的9-氮杂双环3.3.1壬南-3α-苯基苯基氨基甲酸酯类似物作为σ2受体配体:合成体外表征以及作为PET成像和化学增敏剂的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs were synthesized. Among them, >WC-26 and >WC-59 were identified as the most potent σ2 receptor ligands (Ki = 2.58 and 0.82 nM, respectively) with high selectivity against σ1 (Ki of σ1/σ2 ratio = 557 and 2,087, respectively). [18F]>WC-59 was radiolabeled via a nucleophilic substitution of a mesylate precursor by [18F]fluoride, and in vitro direct binding studies of [18F]>WC-59 were conducted using membrane preparations from murine EMT-6 solid breast tumors. The results indicate that [18F]>WC-59 binds specifically to σ2 receptors in vitro (Kd = ~2 nM). Biodistribution studies of [18F]>WC-59 in EMT-6 tumor-bearing mice indicated that the tracer was a less suitable candidate for clinical imaging studies than existing F-18 labeled σ2 receptor ligands. The ability of >WC-26 to enhance the cytotoxic effects of the chemotherapy drug, doxorubicin, was evaluated in cell culture using the mouse breast tumor EMT-6 and the human tumor MDA-MB435. >WC-26 greatly increased the ability of doxorubicin to kill these two tumor cell lines in vitro. These results indicate that >WC-26 is potentially a useful chemosensitizer for the treatment of cancer when combined with conventional chemotherapeutics.
机译:合成了一系列的N-取代的9-氮杂双环[3.3.1]壬南-3α-苯基苯基氨基甲酸酯类似物。其中,> WC-26 和> WC-59 被确定为对σ1(Ki)具有高选择性的最有效的σ2受体配体(分别为Ki = 2.58和0.82 nM)。 σ1/σ2比分别为557和2,087)。 [ 18 F] > WC-59 通过[ 18 F]氟化物的甲磺酸盐前体的亲核取代进行放射性标记,并在体外直接结合[ 18 F] > WC-59 的研究使用的是鼠EMT-6实体乳腺肿瘤的膜制剂。结果表明,[ 18 F] > WC-59 在体外与σ2受体特异性结合(Kd =〜2 nM)。 [ 18 F] > WC-59 在EMT-6荷瘤小鼠中的生物分布研究表明,与现有的F-18相比,示踪剂不太适合用于临床成像研究标记的σ2受体配体。使用小鼠乳腺肿瘤EMT-6和人肿瘤MDA-MB435在细胞培养中评估了> WC-26 增强化疗药物多柔比星的细胞毒性作用的能力。 > WC-26 大大提高了阿霉素在体外杀死这两种肿瘤细胞系的能力。这些结果表明,> WC-26 与常规化学疗法联合使用时,可能是一种有用的化学增敏剂,用于治疗癌症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号